Safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit COVID-19 vaccine in healthy 12–17 year-old adolescents-Reference-Cited by-同舟云学术

Safety and immunogenicity of SCB-2019, an adjuvanted, recombinant SARS-CoV-2 trimeric S-protein subunit COVID-19 vaccine in healthy 12–17 year-old adolescents

Published:2023-01-02 Issue:1 Volume:19 Page:
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Lopez Pio¹,Bravo Lulu²,Buntinx Erik³,Borja-Tabora Charissa⁴,Velasquez Hector⁵,Rodriquez Edith Johana⁵,Rodriguez Camilo A.⁶,Carlos Josefina⁷,Montellano May Emmeline B.⁸,Alberto Edison R.⁹,Salvani-Bautista Milagros⁷,Huang Yung¹⁰,Hu Branda¹⁰,Li Ping¹⁰,Han Htay Htay¹⁰,Baccarini Carmen¹⁰,Smolenov Igor¹⁰^ORCID

Affiliation:

1. Centro de Estudios en Infectología Pediátrica, Universidad Del Valle Clínica Imbanaco, Cali, Colombia

2. College of Medicine, University of the Philippines Manila, Ermita, The Philippines

3. Anima Research Center, Alken, Belgium

4. Asian Hospital and Medical Center, Muntinlupa, Philippines

5. Center of Attention in Medical Research (CAIMED), Bogotá, Colombia

6. Policlínico Social del Norte, Bogotá, Colombia

7. University of the East Ramon Magsaysay Memorial Medical Center, Quezon City, The Philippines

8. Far Eastern University Hospital - Nicanor Reyes Medical Foundation, Quezon City, The Philippines

9. Tropical Disease Foundation-HIMC, Cavite City, The Philippines

10. Clover Biopharmaceuticals, Boston, MA, USA

Funder

Epidemic Preparedness Innovations

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2023.2206359

Reference19 articles.

1. Variation in the COVID-19 infection–fatality ratio by age, time, and geography during the pre-vaccine era: a systematic analysis

2. Global Impact of Coronavirus Disease 2019 Infection Requiring Admission to the ICU

3. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19

4. Cell entry mechanisms of SARS-CoV-2

5. S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and limitations of repurposed drugs and vaccines for COVID-19;Journal of Medicine, Surgery, and Public Health;2024-04

2. Immunogenicity and safety of adjuvant-associated COVID-19 vaccines: A systematic review and meta-analysis of randomized controlled trials;Heliyon;2023-12